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Purpose: To review available data using bendamustine alone and in combination with other 
chemotherapeutic agents in treatment of patients with non-Hodgkin’s lymphomas.
Methods: Internet database searches and literature review.
Results: Bendamustine was approved in March 2008 by the United States Food and Drug 
Administration for the treatment of patients with chronic lymphocytic leukemia. Many trials 
have been performed over the last decade using bendamustine not only as monotherapy, but also 
in combination with other agents including rituximab, vincristine, mitoxantrone, fludarabine, 
and other agents as therapy for patients with relapsed non-Hodgkin’s lymphomas, and recently 
was approved for use in therapy of patients with relapsed indolent lymphomas considered 
refractory to rituximab therapy. As monotherapy, bendamustine induces good responses with 
only minor side effects. In combination with other agents, efficacy improves, especially when 
given in combination with rituximab. The drug has also been studied in combination with 
rituximab as initial therapy for indolent lymphomas, and has excellent activity with less toxicity 
than R-CHOP (rituximab – cyclophosphamide, hydroxydaunorubicin [Adriamycin], Oncovin 
[vincristine], and prednisone/prednisolone).
Conclusion: Overall, bendamustine has demonstrated promising results as therapy for non-
Hodgkin’s lymphomas and should be included in the armamentarium of agents used to treat 
relapsed indolent non-Hodgkin’s lymphomas and may prove valuable as initial therapy for 
these diseases. Further studies are being conducted to demonstrate the efficacy of this drug in 
combination with other agents.
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Indolent non-Hodgkin’s lymphomas: Problems 
in choosing therapy
Non-Hodgkin’s lymphomas (NHL) are the most frequently occurring hematologic 
malignancies in the United States (US), responsible for approximately 19,000 deaths 
per year, with about 66,000 new cases in 2008. Since the 1970s, the incidence of 
NHLs has nearly doubled, increasing about 3%–4% per year.1 Even though some of 
this increase may be related to an increase in the incidence of acquired immunodefi-
ciency syndrome (AIDS), for the most part, the main reason for this rise is unknown. 
Excluding cutaneous malignancies, NHLs are the fifth leading cause of new cancers 
in US, and the ninth leading cause of cancer death in males and seventh in females. 
Prior to the development of rituximab 1-, 5-, and 10-year survival rates were 
approximately 79%, 63%, and 51%, respectively.2 Indolent B-cell lymphomas account 
for approximately 30%–40% of the NHLs. After an initial response to a variety of OncoTargets and Therapy 2009:2 270
Hagemeister and Manoukian Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
medications, most patients develop relapse, and response to 
second-line therapy is often incomplete, with shorter last-
ing remissions following subsequent treatments. Tolerance 
to relapse therapy is often poor, and resistance to standard 
agents develops in most; therefore, newer agents associated 
with good response rates and with low toxicity profiles are 
needed.
Mechanism of action 
of bendamustine
Pharmacodynamics
Bendamustine consists of three distinct structural groups: 
a purine analog-like benzimidazole ring, an alkylating 
agent group, and a water soluble alkane carboxylic chain. 
Bendamustine is categorized as an alkylating agent, causing 
intra- and interstrand DNA cross-links, leading to disrup-
tion of DNA matrix function and DNA synthesis.3 The drug 
causes more cross-linking then other alkylators; this seems 
to be more durable and more difficult to repair than those 
induced by carmustine and cyclophosphamide.4 However, 
unlike other alkylating agents, bendamustine also causes 
activation of DNA damage via stress response and apoptosis 
pathways, inhibition of mitotic checkpoints, and induction of 
mitotic catastrophe.5 As compared to equitoxic concentrations 
of phosphoramide mustard and chlorambucil, bendamustine 
more strongly induces genes responsible for apoptosis. 
Bendamustine also leads to phosphorylation of Ser-15 and 
increases protein expression of Bax, both of which play a role 
in p53-induced apoptosis, and inhibits mitotic check points 
by inhibiting several mitosis-related genes.5,6
Pharmacokinetics
The drug is available as an intravenous formulation, infused 
over 30–60 minutes; peak plasma concentration (Cmax) occurs 
at the end of the infusion.7 It has been studied in treatment 
of hematologic malignancies at doses of 50–60 mg/m2 daily 
for three or five days every four weeks, or 100–120 mg/m2 
daily for two days, every three weeks, whereas in solid 
tumors, doses were higher (120–150 mg/m2 daily, every 
four weeks). Bendamustine is highly protein bound, mainly 
to albumin, and protein binding is not affected by older 
age (70 years) or by low serum albumin levels; however, 
unbound bendamustine is the only form that is active.8,9 After 
a single dose of 120 mg/m2, the intermediate terminal half 
life of the parent compound is approximately 40 minutes, 
with initial elimination via the kidneys, although the drug 
has not been studied in patients with renal failure.6,8,10 
Bendamustine also undergoes extensive first pass hepatic 
metabolism, primarily by hydrolysis, via the cytochrome 
p450 system, and it should be given cautiously to patients 
with significant hepatic dysfunction.7,11 The major metabolite 
is β-hydroxybendamustine, which is also cytotoxic but does 
not contribute significantly to the drug’s activity, since con-
centrations of this metabolite are well below that of the parent 
compound.7 Phase II conjugation with glutathione also plays 
an important role in metabolism; preclinical radiolabeled 
bendamustine studies showed that approximately 90% of the 
drug administered was recovered primarily in the feces.7,9
Clinical trials of bendamustine 
for therapy of relapsed NHL
Monotherapy: Phase ii trials (Table 1)
The types of patients in trials of bendamustine for treat-
ment of NHL have varied, probably accounting for some of 
the differences in results among studies. Overall response 
rates (OR) have varied from 73% to 100%; complete 
response rates (CR) have varied from 11% to 34%, with 
partial response rates (PR) from 43% to 62%. The median 
duration of response (DR) in these trials also varied from 
6.7 to 39 months. Many of the phase I/II studies of benda-
mustine in the treatment of NHL were reported in the mid 
1990s; investigators in Germany also studied the drug as 
monotherapy in treatment of chronic lymphocytic leukemia 
(CLL) in a randomized trial compared with chlorambucil. 
Because of the results of this trial, the drug was approved 
by the American Food and Drug Administration (FDA) for 
therapy of CLL in the US. Investigators in the US have also 
studied the drug as monotherapy for patients with relapsed 
indolent lymphoma; results of these two rigorous studies have 
confirmed that bendamustine is an active agent in treatment 
of indolent lymphomas in relapse, and can be administered 
with the advantage of good tolerance, with the only major side 
effects being modest myelosuppression at the doses suggested 
in these trials, and minimal non-hematologic toxicity, making 
it a potential drug to combine with other agents in therapy of 
lymphomas. Moreover, many of these trials were conducted 
in patients known to have disease considered resistant 
to rituximab, a population with disease often difficult to treat.
european trials of bendamustine 
for relapsed NHL
Although bendamustine was invented in the 1960s, studies 
documenting its true effectiveness did not begin in earnest 
until the 1990s. In 2001, Heider and Niederle reported on a 
phase II trial of bendamustine in therapy of 58 patients with OncoTargets and Therapy 2009:2 271
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relapsed NHL, using 120 mg/m2 daily, given days 1 and 2 on a 
three-week cycle.12 Fifty-two of these patients were evaluable 
and all had at least one prior therapy. The median number 
of treatments prior to bendamustine was one (range 1–6), 
but the median interval from the end of prior therapy to 
bendamustine was only three months. The median number 
of bendamustine cycles was six (range 1–11), and the median 
follow-up time was 24 months (range 1–67). Results were 
impressive when compared to those for other single agents in 
a comparably treated population in prior studies: the OR was 
73%, with 11% CR, and 62% PR. Purine analogs (cladrib-
ine, pentostatin, fludarabine) have provided 30%–70% 
response rates in similar populations; CR was uncommon 
in these studies, and occasionally associated with opportu-
nistic infections, not reported by Heider and Niederle.13–16 
Weidmann and colleagues also reported results of a phase II 
trial with bendamustine for patients with relapsed aggressive 
lymphomas using 120 mg/m2 daily on days 1 and 2, every 
three weeks.17 Most of these patients were judged as ineli-
gible for aggressive combinations of therapy or were known 
to have drug-resistant disease. Twelve of them had diffuse 
large cell lymphoma (DLCL) and three had human immu-
nodeficiency virus-positive serologies. Of the 18 evaluable 
patients on this study, 44% (8/18) had a response: 17% with 
CR and 28% with PR. Only four of the patients had disease 
refractory to previous treatment and all four had a response 
to bendamustine, two with CR and two with PR. The median 
DR was not reported in this trial; however, response dura-
tions in the three patients in CR were 6, 8+, and 27+ months. 
In this study, grades 3–4 hematologic toxicities occurred in 
up to 13% of the patients, and the drug was discontinued in 
two due to prolonged thrombocytopenia and leukopenia. 
No grade 4 nonhematologic adverse events were reported, 
and grade 3 nonhematologic toxicities occurred in less than 
10% of the patients. In this population, investigators have 
reported response rates of 30% or less, and CRs are rare in 
patients with refractory disease.18–24 Both of these studies 
documented that the drug is an active single agent in treat-
ment of a wide variety of NHLs, and encouraged exploration 
of its use in other studies, as a single agent and in combina-
tions with other drugs.
In another phase II trial, using a lower dose of benda-
mustine, but a longer duration of treatment, Bremer and 
colleagues administered bendamustine at 60 mg/m2 daily for 
five days at four-week intervals in 62 patients with relapsed 
lymphoproliferative disorders, including mostly patients with 
myelomas or immunocytomas (also known as lymphoplas-
macytic lymphomas [LPL]).7 The median number of treat-
ments was two (range 1–10) and most of these patients had 
previously received chlorambucil, with or without prednisone, 
or melphalan, both alkylating agents. They reported an OR 
of 82% with a CR of 15%, PR of 67%, and a median DR of 
39 months: for the 62 patients with NHL, the OR was 82%, 
with a median DR of 39 months. Although the authors con-
cluded that this dose and schedule may have produced longer 
DRs than those employed by Heider and Niederle and others, 
histologies were not comparable, and it is difficult to conclude 
which schedule might best exploit the value of this drug. 
Furthermore, a five-day schedule is perhaps less convenient 
than a two-day schedule, and without additional studies, it is 
difficult to reach any conclusion about this trial. Nonetheless, 
this study suggests the value of this drug in management of 
yet two more histologies, myeloma and LPL.
North American trials of bendamustine 
for relapsed NHL
Rituximab refractoriness may become an important deter-
minant of response for relapsed lymphomas, not only for 
Table 1 Phase ii trials of bendamustine as monotherapy for patients with relapsed or refractory NHL
Author Dose  
(mg/m2)
Schedule of  
drug delivery
Number of  
patients
% OR % CR Remission duration 
(median, months)
Heider and Niederle12 120 Days 1, 2  
Q three weeks
52 73 11 16
Bremer7 60 Days 1–5  
Q four weeks
62 82 15 39
weidmann17 120 Days 1,2  
Q three weeks
18 44 17 Nr
Friedberg26 120 Days 1,2  
Q three weeks
74 77 34 6.7
Kahl27 120 Days 1,2  
Q three weeks
100 76 33 9.2
Abbreviations: Cr, complete response; NHL, non-Hodgkin’s lymphoma; Or, overall response; Q, .OncoTargets and Therapy 2009:2 272
Hagemeister and Manoukian Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
indolent, but also aggressive lymphomas.22,25 In 2007, 
Friedberg and colleagues reported results of a phase II trial 
using bendamustine, 120 mg/m2 daily on days 1 and 2, given 
every three weeks, as therapy for 76 evaluable patients with 
rituximab-refractory indolent or transformed NHL.26 In this 
multicenter study, rituximab refractoriness was defined as 
no response or progression within six months of complet-
ing rituximab therapy, alone or combined with other drugs. 
Histologies included indolent phenotypes (follicular [FL], 
61%; small lymphocytic [SLL], 16%; marginal zone [MZL], 
3%; other, 14%) and transformed lymphomas. The median 
number of prior therapies was two (range 1–5) and prior treat-
ments included single-agent rituximab (76%), CHOP-like or 
CVP (cyclophosphamide, prednisone, vincristine) therapy 
with or without rituximab (82%), autologous stem cell trans-
plant (ASCT, 8%), and radioimmunotherapy (RIT, 12%). 
In the 74 patients evaluable for response, the OR was 77%, 
with a CR of 34% and PR of 43%. The median DR was 
6.7 months for all responders; for those with disease consid-
ered refractory to prior alkylator therapy, it was 61%, with a 
CR of 30%. The median progression-free survival (PFS) rate 
was 7.1 months; it was 4.2 months for patients with trans-
formed disease and 8.3 for those with indolent lymphomas. In 
this trial, the median number of cycles of therapy per patient 
was five (range 1–9). Primary side effects included reversible 
myelosuppression, with grades 3–4 neutropenia (54%), 
febrile neutropenia (7%), and thrombocytopenia (25%). 
Three patients who had previously received extensive therapy 
have developed myelodysplastic syndrome or leukemia. This 
study was important because it was the first trial evaluating 
a chemotherapeutic agent in a group of patients with disease 
considered refractory to rituximab, and encouraged the piv-
otal trial in the US that enabled approval of bendamustine 
in therapy of relapsed indolent lymphomas.
The pivotal study leading to approval by the FDA of 
bendamustine for therapy of relapsed indolent lymphomas 
in the US was a multicenter, single-armed trial, conducted 
by Kahl and colleagues in 100 patients; rituximab resistance 
was defined as no response or progression within six months 
of 1) receiving the first dose of a full course of rituximab 
induction, 2) completion of rituximab maintenance therapy 
or progression before the next scheduled rituximab dose, or 
3) completion of a full course of the combination of rituximab 
and chemotherapy.27 Patients could have received additional 
systemic therapy after the qualifying rituximab regimen. The 
treatment program was similar to that used in the trial described 
by Friedberg and colleagues, with administration of 120 mg/m2 
of bendamustine daily on days 1 and 2, every three weeks; 
the plan was to administer only six cycles, although patients 
could receive a maximum of eight cycles if clinical benefit was 
observed. Histologies included FL (62%), SLL (21%), MZL 
(16%), and LPL (1%). In this population, the median number of 
prior rituximab-containing regimens was two (range 1–6), and 
the number of prior chemotherapy regimens administered was 
two (range 0–6). Twenty-four percent had previously received 
RIT, and 36% were considered to have disease considered 
refractory to their last chemotherapy regimen. The FLIPI 
index was also studied in the patients with FL prior to relapse 
therapy.28 Response rates were high, as in other trials, ranging 
from 71%–100% for various histologies. Complete response 
rates by histologies were: FL (20%), SLL (5%), nodal MZL 
(11%), and extranodal MZL (43%). The OR for patients known 
to have disease considered refractory to their last chemotherapy 
regimen (that is, no CR or PR) was 64%, including 6% CR, 
and 88% for those known to have chemosensitive disease, with 
30% CR. In this trial, the FLIPI score at the time of relapse did 
not predict which patients would respond or enter CR: the CR 
rate for those FLIPI scores of 2 was 27%, and for those with 
FLIPI scores of 3 or more, it was 23%. The median DR for all 
patients was 6.3 months, and the median PFS was 7.5 months. 
Grades 3–4 hematologic toxicities were the only major side 
effects, and similar to those noted in the study reported by 
Friedberg and colleagues. The use of growth factors was not 
specified in the study: 15% had grade 3 infections, and 6% 
grade 4. Based on the results of this trial, bendamustine was 
approved for therapy of indolent lymphomas in relapse fol-
lowing documentation of rituximab-based resistance. More 
importantly, results of this study and that of Friedberg and 
colleagues paved the way for development of other protocols 
in the US, many of which are still ongoing.
Bendamustine in combination with other 
agents for relapsed NHL: Phase ii trials 
(Table 2)
As with most drugs used in therapy of patients with B-cell 
lymphomas, rituximab is often the first drug to be added to 
its administration schema, in hopes that the combination of 
rituximab plus the drug in question will benefit the patient 
population by delivering a higher response rate, especially 
CR, and a longer DR. Few trials have addressed this pos-
sibility in a randomized fashion for relapsed disease using 
single agent therapy, although investigators have documented 
this principle in treatment of patients with combination 
chemotherapy.29,30 Therefore, when bendamustine was found 
to be an active agent, it was combined with rituximab and 
other agents in phase II trials. In these studies, most of OncoTargets and Therapy 2009:2 273
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which were conducted in Europe prior to the approval of 
bendamustine by the FDA in the US, and some of which were 
published only in German, it is not clear that the addition of 
other chemotherapy agents to the combination of rituximab 
and bendamustine (BR) provided any major benefit over that 
expected with BR alone, suggesting that further studies would 
be needed to determine the best combination of drugs to use 
for patients with relapsed NHL when treated with BR.
Bendamustine and rituximab  
for relapsed NHL
Rummel and colleagues performed in vitro studies demon-
strating that rituximab enhances the activity of bendamus-
tine in a synergistic fashion.31 They found that the doses 
of bendamustine required to induce apoptosis in DOHH-2 
cells was halved when rituximab was added to the media, 
with similar effects demonstrated in studies with freshly 
isolated B-CLL cells. Based on this observation, they treated 
a group of patients with relapsed or refractory low-grade 
or mantle cell lymphomas using the BR combination.32 
In this trial, 63 eligible patients, 30% of whom had disease 
considered refractory to their last chemotherapy, received the 
BR regimen, using bendamustine 90 mg/m2 daily on days 1 
and 2, with the standard dose of rituximab, 375 mg/m2 on 
day 1, given every four weeks. Patients received a maximum 
of four cycles. Histologies included FL (38%), MCL (25%), 
LPL (27%), and MZL (10%). The OR was 90%, with a CR 
or 60%, and a median PFS of 24 months. This PFS was 
significantly longer that that reported following the patients’ 
treatments prior to BR (nine months). OR and CR rates in 
this trial for various histologies were: FL, 96% and 71%; 
LPL (also designated small lymphocytic), 100% and 53%; 
MCL, 75% and 50%; and MZL, 83% and 67%, respectively. 
Interestingly, the median PFS was 18 months for those 
with MCL, whereas the median PFS for patients with 
FL and LPL had not been reached, with a median follow-up 
of 20 months. In an updated analysis of the data, the median 
duration of survival had not been reached, with a median PFS 
of 30 months.33 Grades 3–4 toxicities were assessed per cycle: 
neutropenia occurred in 16% of cycles, thrombocytopenia 
in 3%, and anemia in only 1%. Most importantly, no growth 
factors were administered during the course of this trial. This 
group of investigators is also conducting an ongoing trial 
of BR in the treatment of patients aged over 75 years. In a 
recent analysis, 30% of the patients enrolled had FL and 18% 
MCL, and 36% of these patients had received prior therapy.34 
In this report regarding 33 evaluable patients, the OR was 
91%, with 30% CR. One patient died during the first cycle 
of therapy of neutropenic fever; otherwise, the safety pro-
file of this regimen was similar to that reported for younger 
patients, suggesting that it might be an ideal regimen for the 
older patient, especially one with co-morbid health issues 
that might preclude more intensive therapy.
Lakner and colleagues have also conducted a prospective 
trial of BR in therapy of relapsed or refractory indolent and 
MCL, using 90 mg/m2 of bendamustine on days 1 and 2, and 
rituximab at the standard dose of 375 mg/m2 on day 1.35 The 
median age was 69, and histologies included FL (25 patients), 
MCL (10), LPL (8), and MZL (3). The OR was 85%, with 
43% CR, and the median event-free survival (EFS) result was 
nine months (range, 0–39), with a PFS of 12 months. These 
results are very similar to those reported by Rummel and 
colleagues, and provide further evidence of the effectiveness 
of this regimen; however, more importantly, the combination 
is not associated with cardiac, pulmonary, renal, or hepatic 
toxicity, an outcome similar to that expected with these drugs 
when used as single agents.
Mohren and colleagues have evaluated the safety and 
efficacy of another method of administration of bendamus-
tine and rituximab in treatment of 10 evaluable patients 
Table 2 Phase i/ii trials of bendamustine in combination with other agents in therapy of relapsed and refractory NHL
Authors Other agents used 
in trials
Number of 
patients
% OR % CR Duration of response 
(median, months)
rummel31,32 rituximab 166 90 60 PFS 30 months
Lakner35 rituximab 46 85 43 PFS 12 months
Mohren36 rituximab 10 70 40 Nr
robinson37 rituximab 66 92 54 21
Koenigsman38 Fludarabine 29 77 45 14
weide42 Mitoxantrone, rituximab 55 89 35 PFS 19 months
Matous47 Bortezomib, rituximab 16 80 53 Nr
Abbreviations: Cr, complete response; NHL, non-Hodgkin’s lymphoma; Nr, no response; Or, overall response; PFS, progression-free survival.OncoTargets and Therapy 2009:2 274
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with relapsed or refractory aggressive NHLs.36 All patients 
enrolled had previously received at least one treatment that 
included an anthracycline. Patients received bendamustine 
60 mg/m2 on days 1, 8, and 15 every four weeks, and ritux-
imab 375 mg/m2 on days 1, 8, 15, and 22 during the first 
cycle only. In this study, three had a PR, four had CR, and 
three of those entering CR are still in remission at six, 18, 
and 33 months. Further evaluation of this treatment schedule 
would be of significant interest.
North American trial
In a phase II multicenter study of BR, using similar doses and 
schedules of drugs to Rummel and colleagues, investigators 
treated 66 patients with relapsed indolent and mantle cell 
lymphomas: none had disease considered to be refractory 
to rituximab.37 The median age was 60 years (40–84 years), 
and the median number of cycles was six (2–7 cycles). The 
OR was 92%, with 54% CR. Overall response and CR rates 
for 54 with indolent histologies were 93% and 54%; corre-
sponding results for the 12 with MCL were 92% and 59%. 
More importantly, there were only minor differences between 
the results for those who had previously received rituximab 
and those who had not, including ORs of 87% and 100%, 
and CRs of 49% and 62%, respectively. The median follow-
up time on this trial was 20 months, with a median DR of 
21 months for all patients, and 21 and 19 months for those 
with indolent and MCL, respectively. In this study, febrile 
neutropenia was rare (7%) despite the fact that grades 3–4 
neutropenia occurred in 37%, a finding common to most trials 
that include bendamustine as a single agent or in combination 
with rituximab. Importantly, growth factor or blood product 
support was administered during only 9% of the cycles, 
and only 12% of the patients received granulocyte growth 
factors, increasingly used as the number of treatment cycles 
increased. Five deaths occurred in this trial, causes including 
disease progression (three patients), compartment syndrome 
(one), and toxic epidermal necrolysis (one): the last of these 
occurred in the setting of multiple drug administrations, 
including allopurinol, a drug associated with this type of 
complication of therapy. Regardless, reports of this compli-
cation prompted a warning in the package insert regarding 
the safety of bendamustine.
Bendamustine and other chemotherapy 
agents for relapsed or refractory NHL
Bendamustine and fludarabine
In a phase I/II trial, Koenigsman and colleagues reported 
results of therapy for 29 patients using bendamustine 
and fludarabine.38 This combination was chosen because 
the investigators hypothesized that the alkylating activity 
of bendamustine could be enhanced when combined with 
a purine analog; incorporation of the analog might prevent 
normal DNA synthesis, thereby increasing the alkylating 
agent’s activity, an observation noted with in vitro studies 
of apoptosis using the two drugs in combination.39–41 Two 
dose levels of bendamustine were employed, 30 mg/m2 (nine 
patients) and 40 mg/m2 (20 patients), and all received fluda-
rabine at 30 mg/m2. Each drug was administered on days 
1, 2, and 3, and plans were to administer the combination 
every four weeks for a maximum of six cycles. Fourteen 
were considered to have chemotherapy-refractory disease, 
and 14 had previously received anti-CD20 therapy; six had 
undergone prior ASCT. The toxicity of the regimen was 
mainly hematologic, and no growth factors were used in this 
trial. Nine of 19 evaluable patients had grade 3, and five had 
grade 4 hematotoxicities, with grades 3–4 thrombocytopenia 
in 2% of the cycles and grades 3–4 neutropenia in 25%. 
Eighteen percent of the patients in the phase I portion of 
this trial experienced febrile neutropenia, and one in the 
phase II portion died of neutropenic sepsis. There was also 
a tendency for patients to experience cumulative cytotox-
icity with the administration of more treatment cycles. Of 
22 patients evaluable for response, the OR was 77%, with 
45% CR, and 70% of all patients required a maximum 
of four cycles for best response; 10 patients were unable 
to receive 6 cycles as intended because of myelotoxicity. 
The authors recommended that this combination, using 
30 mg/m2 of each drug, was effective in treatment of indo-
lent and MCL, but warned that the fewer number of cycles 
given to achieve response, the better the combination would 
be tolerated.
Bendamustine, mitoxantrone, and rituximab
Weide and co-workers have studied this combination in 
therapy of patients with relapsed or refractory indolent or 
MCL or CLL, in a phase I/II single center study, and have 
reported results of a phase II multicenter trial.42–44 In the 
former study, 20 patients were treated within the phase I 
aspect of the trial, and 34 received the doses determined 
for the phase II portion, using bendamustine 90 mg/m2 
daily for patients with NHL and 80 mg/m2 for those with 
CLL, days 1 and 2, mitoxantrone 10 mg/m2 on day 1, and 
rituximab 375 mg/m2 on days 8, 15, 22, and 29.42,43 From 
days 36 on, patients received only bendamustine and mito-
xantrone every 4 weeks as with the first cycle of therapy, 
for a maximum of six cycles. Histologies included indolent OncoTargets and Therapy 2009:2 275
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NHL (26 patients), transformed NHL (six), B-cell CLL (21), 
and prolymphocytic leukemia (one). Fludarabine had been 
previously administered to 12% of those with indolent NHL, 
27% of those with leukemias, and 17% of the patients with 
transformed NHL: only five patients had previously received 
rituximab. The OR for all patients on this trial was 96%, with 
a CR of 41%. The CR rate for FL was 57%; for transformed 
NHL it was 33%, and was 50% and 75% for those with LPL 
and MCL/MZL, respectively. The median time to progres-
sion (TTP) was 7.5 months in those with transformed NHL, 
but had not been reached in the indolent NHL group after a 
median follow-up of 27 months. This last group had a median 
time to next treatment result of only 6.5 months with the 
therapy given to them immediately prior to BMR.
In the subsequent phase II, multicenter trial, Weide and 
colleagues treated 57 patients with relapsed or refractory 
indolent and MCL, using BMR differently than that originally 
described (bendamustine 90 mg/m2 days 1 and 2, mitoxan-
trone 10 mg/m2 on day 1, rituximab 375 mg/m2 on day 8), 
with cycles repeated every four weeks, for a total of four 
cycles.44 Overall, 39% had previously received rituximab, 
although only two were considered to have disease that was 
resistant to that drug. Of the 55 evaluable patients, the OR 
was 89%, with 35% CR, and the median PFS 19 months, with 
a median overall survival (OS) of 33 months. OR and CR 
rates for those with MCL (18 patients) and FL (27 patients) 
were 78% and 33%, and 92% and 50%, respectively. Median 
PFS and OS results were 21 and 31 months, and 17 months 
and not reached, respectively, with a median follow-up time 
of 27 months (1–43 months). Interestingly, results for those 
who had previously received rituximab were similar to those 
for patients who had not. In this trial, as would be expected, 
grades 3–4 hematologic toxicities included granulocytopenia 
in 46%, and thrombocytopenia in 16%, with grade 3 nonhe-
matologic toxicities in less than 6% for each type and none 
that were grade 4 in severity. Although the response rates for 
this combination may seem to be excellent, it is unclear what 
mitoxantrone adds to this combination, and only a random-
ized trial of BMR and BR would answer the question as to 
which might produce better results for these patients.
Bendamustine and bortezomib  
for relapsed or refractory NHL
Moosmann and colleagues have recently reported results of 
a phase I/II trial of nine patients with relapsed (five patients) 
or refractory (four patients) indolent or MCL.44 In this group 
of heavily pretreated patients, seven had already received 
rituximab, two prior bortezomib, two ASCT, and two RIT. 
Treatment consisted of bendamustine 60 mg/m2 (phase I) 
escalated to 80 mg/m2 (phase II) on days 1, 8, and 15 and 
bortezomib 1.6 mg/m2 on days 1, 8, 15, and 22; a similar trial 
has suggested that, when combined with rituximab, higher 
doses of bortezomib given weekly may be as effective as 
lower doses given twice weekly, with less toxicity.46 Dose-
limiting toxicities with this combination included diarrhea, 
fatigue, and thrombocytopenia; however, there were no seri-
ous infectious or neuropathic serious adverse events in this 
study. The phase II portion of this trial is ongoing.
Bendamustine, bortezomib, and rituximab 
for relapsed or refractory follicular lymphomas
In this single-armed multicenter trial, also known as the 
VERTICAL study, Matous and colleagues have treated 
16 patients with relapsed or refractory FL, all of whom 
had previously undergone ASCT for relapse, and had 
previously received rituximab, 63% of whom had disease 
considered refractory to the antibody.47 As opposed to the 
patient selection in the study by Moosmann and colleagues, 
no patient enrolled on this study could have previously 
received bortezomib or bendamustine. This phase I/II study 
was designed to find the optimal, maximally tolerated dose 
of bendamustine that could be administered to patients 
receiving bortezomib 1.6 mg/m2 on days 1, 8, 15, and 
22 every 35 days, with the bendamustine administered on 
days 1 and 2, another difference between this trial and the 
study by Moosmann and colleagues. The maximum tolerated 
dose of bendamustine was primarily defined by duration 
of hematologic toxicity, and, based on this study, was 
90 mg/m2. Rituximab 375 mg/m2 was administered during 
the first cycle on days 1, 8, 15, and 22, and in subsequent 
cycles was given only on day 1. The regimen was associated 
with grades 3–4 neutropenia and thrombocytopenia in 25% 
and 12%, respectively, and the median number of cycles 
administered was five. Peripheral neuropathy occurred in 
44% of the patients, with a median time to onset of 12 weeks; 
however, it resolved in all who had grades 1–2 neuropathy, 
and persisted in only one who had grade 3 neuropathy and 
discontinued therapy. Overall, 80% of the patients had a 
response, with 53% CR, and response rates were not clearly 
related to the dose of bendamustine administered. Responses 
occurred within the first three cycles of therapy in most 
patients: six of the 12 responders had disease considered 
refractory to their last rituximab-containing treatment. This 
is an ongoing trial; the regimen has not been compared to 
the BR regimen, and only a randomized study can determine 
the value of bortezomib in this combination.OncoTargets and Therapy 2009:2 276
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Clinical trials of bendamustine 
in combination with other agents 
as initial therapy for patients with 
NHL (Table 3)
Bendamustine, vincristine, and prednisone 
for therapy of indolent and MCL
In a phase III trial, patients with stage III–IV indolent or 
MCL received therapy that was randomized to benda-
mustine, vincristine, and prednisone (BOP, 82 patients) 
versus cyclophosphamide, vincristine, and prednisone 
(COP, 80 patients).48 A maximum of eight cycles of therapy 
was planned on each arm of this trial. Overall, 86% had 
stage IV disease; 50% had FL, 27% had MCL, and 23% 
had LPL. Requirements for enrollment included presence 
of B symptoms, thrombocytopenia or anemia, rapid tumor 
growth, or bulky disease: exclusions included stage III with 
less than five nodal regions of disease, with all nodes less than 
5 cm in diameter. Doses initially included vincristine 2 mg 
on day 1 and prednisone 100 mg/m2 daily on days 1–5 on 
both arms of this trial. The dose of cyclophosphamide on the 
COP regimen was 400 mg/m2 daily intravenously on days 1–5 
for all cycles of therapy; however, the original protocol dose 
of bendamustine was 70 mg/m2 daily on days 1–5. Due to 
significantly more thrombocytopenia with BOP than COP 
after enrollment of 25 patients onto this trial, the dose of 
bendamustine was reduced to 60 mg/m2 daily on days 1–5 in 
all subsequent cycles of BOP. To further complicate matters, 
interferon maintenance was to be administered to all patients 
who entered CR or PR on this trial; of 115 eligible patients, 
only 28 actually received this drug. Regardless of the 
drawbacks to the design and performance of this trial, 
BOP was as effective as COP at inducing remissions: OR 
and CR rates were 66% and 22% (BOP) versus 76% and 
20% (COP), respectively (P = 0.1). Of note, a patient who 
might be considered as having a CRu in US trials might be 
considered as having a PR in this study. The five-year TTP 
result for responders to BOP was 59% compared to 46% for 
those responders who received COP (P = 0.037). EFS results 
were affected by the administration of interferon: respond-
ers who received BOP or COP had similar results, but those 
who responded to BOP had longer time to treatment failure 
than did those who responded to COP. Five-year overall 
survival rates were similar on the two arms of this trial, 
although they were better when patients received interferon 
maintenance, and were lower for patients with MCL (46%) 
than they were for those with FL or LPL (66% and 74%, 
respectively). Grades 3–4 toxicities were uncommon, except 
for neutropenia, which occurred more frequently in patients 
receiving COP.
Bendamustine and rituximab as therapy 
for previously untreated indolent and MCL
Rummel and colleagues have conducted a trial that has 
completed accrual for patients with previously untreated 
indolent and MCL, randomizing treatments between 
BR, as originally described by this group in its original 
trial of patients with relapsed disease, and R-CHOP 
(rituximab – cyclophosphamide, doxorubicin, vincris-
tine, prednisone), using standard doses, given every three 
weeks.49,50 Of the first 463 patients enrolled on this trial, 
histologies were equally distributed between both arms: 
these included FL (52%), MCL (19%), LPL/SLL (14%), 
and MZL (13%). In their report of results for the first 315 
patients on this study, BR was not only as effective as R-
CHOP at inducing remissions, with similar OR and CR rates 
for the two arms of this trial, but BR was more tolerable 
than R-CHOP. In this phase III, noninferiority study, the 
OR and CR rates for 162 patients on the BR arm were 93% 
and 47% compared with 93% and 42% for the 149 patients 
receiving R-CHOP. Response rates were similar for both 
treatments for all histologies: OR rates for patients with FL, 
Table 3 Phase iii randomized trials of bendamustine in combination with other agents for previously untreated NHL
Author Combinations used 
in trials
Number of 
patients
% OR % CR Duration of response
Herold48 Bendamustine, 82 66 22 Five-year TTP
vincristine, vs vs vs 59% vs 46% for
prednisone vs COP 80 76 20 responders
rummel49,50 Bendamustine, 162 vs 149 93 47 Median PFS not reached
rituximab vs vs vs vs 39 months for all
r-CHOP 93 42 patients
Abbreviations: COP, cyclophosphamide, vincristine, prednisone; Cr, complete response; NHL, non-Hodgkin’s lymphoma; Or, overall response; PFS, progression-free survival; 
r-CHOP, rituximab – cyclophosphamide, hydroxydaunorubicin [Adriamycin], Oncovin [vincristine], and prednisone/prednisolone;    TTP, time to progression.OncoTargets and Therapy 2009:2 277
Bendamustine in the treatment of non-Hodgkin’s lymphomas Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
LPL/SLL, MCL, and MZL were 96%, 100%, 88%, and 83%, 
respectively; corresponding OR results for those receiving 
R-CHOP were 93%, 86%, 96%, and 100%. CR rates for 
these histologies using BR were 51%, 45%, 42%, and 42%; 
those for patients receiving R-CHOP were 43%, 24%, 41%, 
and 56%. In a follow-up of this trial, response rates were still 
similar to those originally reported by this group.48 With a 
median follow-up of 27 months on both arms of the trial, 
results were not inferior for those patients receiving BR (232 
patients) compared to those for patients receiving R-CHOP 
(224 patients): progression or relapse has been observed in 
63 treated with BR and in 89 treated with R-CHOP. The 
median PFS for those on the R-CHOP arm is 39 months; 
for those who received BR, it has not yet been reached. 
Grades 3–4 neutropenia were observed in 38% and 14% of 
the R-CHOP and BR arms, respectively, and 21% of those 
receiving R-CHOP received granulocyte colony-stimulating 
factor (G-CSF) compared with only 5% of those receiving 
BR. Infectious complications also occurred more frequently 
in those treated with R-CHOP (31% for BR compared with 
41% with R-CHOP, including all grades). Of course, benda-
mustine is not associated with significant cardiac, renal, or 
hepatic toxicity, alopecia does not occur, and neuropathy is 
rare: all of these are toxicities that investigators have reported 
with R-CHOP. Final results of this trial are awaited: patients 
with some histologies may have superior PFS results with one 
or the other regimen, once data is sorted according to various 
histologic subtypes. Results of this trial have also encouraged 
the development of an international confirmatory trial: this 
study may lead to the approval by the FDA of bendamustine 
in combination with rituximab as initial therapy for indolent 
and mantle cell lymphomas.
Bendamustine and rituximab as initial 
therapy for aggressive B-cell NHLs
Following their finding that bendamustine has activity 
in therapy of patients with recurrent aggressive NHLs, 
Weidmann and colleagues conducted a trial in which they 
evaluated the efficacy and safety of BR as initial therapy for 
patients over the age of 80 years who were not considered 
eligible for R-CHOP therapy.51 The dose of bendamustine was 
escalated in this trial compared to the BR regimen described 
by Rummel and colleagues.32 Those with stage I–II disease 
received four cycles of BR every 21 days, using bendamustine 
120 mg/m2 daily on days 2 and 3, with the standard dose of 
rituximab on day 1, followed by involved field radiotherapy. 
Those with stage III–IV disease received the same regi-
men for a total of six cycles, followed by two extra doses 
of rituximab. Twelve of the 14 patients enrolled on this trial 
had DLCL; eight had stage I–II disease. Six (55%) of the 
11 evaluable patients achieved CR, and two (18%) a PR. The 
median PFS was 14.4 months, and the estimated two-year 
OS was 53%. Grades 3–4 neutropenia occurred in only 18% 
of the administered cycles and only 4% developed grade 3 
thrombocytopenia.
Ongoing trials with bendamustine: 
An old drug becomes a new drug
Currently, there are a number of trials which are attempting to 
determine the best way to utilize this drug, invented so long 
ago. Multiple investigators have reported variations of the 
dose administration described by Rummel and colleagues, 
using 90 mg/m2 in combination with rituximab for relapsed 
disease, daily on days 1 and 2; in the original study reported 
by Heider and Niederle and in the North American trials of 
single-agent therapy, the dose was 120 mg/m2, and in the 
trial for B-cell CLL, it was 100 mg/m2. At the present time, 
it is also unclear what the best schedule might be for the 
drug, since most of the single-agent trials have used dosing 
every three weeks, and in the BR trials reported by Rummel 
and colleagues, the drugs are given every four weeks, for 
which the dose of bendamustine is significantly lower than 
that approved by the FDA as a single agent. In combina-
tions that include myelotoxic agents, including fludarabine, 
and anthracyclines, the maximal dose may be 90 mg/m2, as 
suggested by some trials, although allowable dose modifica-
tions and routine use of growth factors may prevent some of 
the associated reported neutropenic episodes and infections 
encountered with multiple agent chemotherapy. However, 
when administered in combination with rituximab, or any 
other antibody, the appropriate dose may well be 90 mg/m2, 
as suggested by Rummel and colleagues, even though higher 
doses of bendamustine might be just as safe as the lower dose 
administered in their trial. Besides safety, other reasons to 
consider adoption of the BR schedule reported by Rummel 
and associates relate to ease of administration, given over two 
days, rather than at lower doses over five days, or weekly, as 
in some trials. In order to demonstrate that alternate regimens 
provide improved results, randomized trials would be needed, 
although it may be difficult to conduct such studies, given the 
number of new drugs available to the treating physician.
Besides tolerability issues, BR may be as good as 
regimens that employ bendamustine and rituximab plus 
some other chemotherapy agent, including fludarabine, 
anthracyclines, and spindle cell toxins. To date, there has 
been no randomized study documenting that any regimen is OncoTargets and Therapy 2009:2 278
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better than the BR combination, and comparisons between 
different studies is difficult, due to wide variability in the 
diseases studied and prior treatments administered to these 
populations. Part of this problem stems from the effectiveness 
of rituximab: almost all regimens, whether single-agent or 
combination therapies, provide better results for patients with 
B-cell NHL when administered with rituximab. Many of the 
studies described above have administered rituximab using 
schemas that are different than those described by Rummel 
and colleagues: one dose prior to each cycle of chemotherapy 
has become a standard of care, although other methods may 
provide better results. It is possible that BOP may be as good 
as COP, as reported by Herold and colleagues; however, this 
study remains primarily of historical interest, especially now 
that rituximab is widely available. Only randomized studies 
can determine the effectiveness of any regimen compared 
to another.
Finally, novel agents for therapy of lymphomas are on 
the horizon: these include protein inhibitors, proteasome 
inhibitors, anti-CD20 antibodies, immunomodulators, and 
antibodies directed against other targets on the cell surface. 
All of these might be agents that could be combined with 
bendamustine, and the VBR trial (bendamustine, bortezomib, 
rituximab) is a good example of newer studies. Hopefully, 
this “old but new” agent will eventually find its proper place 
among the list of drugs available to treat patients with lym-
phoproliferative diseases in our armamentarium, with its 
good tolerability and ease of administration.
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